Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Study Summary

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.